SAN CARLOS, Calif.--(BUSINESS WIRE)--BioTrace Medical, Inc., today announced the company’s key activities at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 meeting, which will take place October 29 - November 2 at the Colorado Convention Center in Denver.
The company’s Tempo® Temporary Pacing Lead will be featured in a breakfast symposium titled: “The Tempo Temporary Pacing Lead: A New Standard of Care in TAVR”, which will be co-chaired by Susheel K. Kodali, M.D., director of the Structural Heart and Valve Center at NewYork-Presbyterian/Columbia University Medical Center, and Steven Yakubov, M.D., system chief, Advanced Structural Heart Disease, Riverside Methodist Hospital/OhioHealth. (Symposium registration: http://www.crf.org/tct/agenda/satellite-programs?programid=1183.)
The symposium will feature recent clinical experience and case studies from several leading U.S. transcatheter valve aortic replacement (TAVR) centers, highlighting the safety and efficacy of the Tempo Lead, and its positive impact on facilitating post-TAVR patient ambulation and reducing length of stay. These results were observed in more than 500 cases with no perforations, pericardial effusions, or sustained device-related arrhythmias reported.
“Temporary pacing following a TAVR procedure is a key element to the recovery process and as the number of TAVR cases increase, so does the need for a temporary pacing technology that mitigates the risks of perforation and lead dislodgement, and that can facilitate ambulation in the recovery process,” said Stanley Chetcuti, M.D., professor of cardiovascular medicine and director of the cardiac catheterization laboratory at the University of Michigan Health System, and a member of the BioTrace symposium faculty at TCT. “Real-world use of the Tempo Lead continues to demonstrate its ability to provide secure and stable pacing both during and after TAVR procedures and, at the University of Michigan we have been impressed with the unparalleled safety and stability of the Tempo Lead.”
The BioTrace Tempo Lead will be featured in the following presentations and events at TCT 2017 (all times are Mountain Time):
Breakfast Symposium
Tuesday, October 31
The
Tempo Temporary Pacing Lead: A New Standard of Care in TAVR
Time/Location:
6:30 a.m. - 8:00 a.m.; Room 607
Co-Chairs:
- Susheel K. Kodali, M.D., NewYork-Presbyterian Hospital/Columbia University Medical Center, New York
- Steven J. Yakubov, M.D., FACC, FSCAI, Riverside Methodist Hospital/OhioHealth, Columbus, Ohio
Faculty:
- Stanley J. Chetcuti, M.D., University of Michigan Health Center, Ann Arbor, MI
- Samir R. Kapadia, M.D., Cleveland Clinic, Cleveland, Ohio
- Tamim M. Nazif, M.D., NewYork-Presbyterian Hospital/Columbia University Medical Center, New York
- Sanjeevan Pasupati, MBChB, FRACP, FCSANZ, Waikato Hospital, Hamilton, New Zealand
- Carlos E. Sanchez, M.D., Riverside Methodist Hospital/OhioHealth, Columbus, Ohio
Oral Presentations
Tuesday, October 31
Didactic
Session: Transcatheter Aortic Valve Therapies, Part 2 - New Technology
Forum – TAVR Systems and Accessory Devices
-
“Advances in Temporary Transvenous Pacemakers: The BioTrace Active
Fixation Lead”
Presenter: Tamim Nazif
Time/Location: 5:32 p.m.; Mile High Ballroom 2B-3B, Ballroom Level
Wednesday, November 1
TCT360:
Transcatheter Aortic Valve Therapies IV Virtual – Complex Case
Management and Clinical Highlights
Virtual Didactic Session II:
TAVR Procedural Considerations
-
“How to Manage Conduction Abnormalities and Pacemaker Implantation
after TAVR”
Presenter: Steven J. Yakubov
Time/Location: 9:24 a.m.; Room 212, Meeting Room Level
Live Cases
Monday, October 30
Intermountain
Heart Institute at Intermountain Medical Center, Salt Lake City, Utah
- 9:00 a.m. and 11:00 a.m. - Structural Theater, Exhibit Hall Level
Thursday, November 2
NewYork-Presbyterian/Columbia
University Medical Center
- 8:45 a.m. and 11:45 a.m. - Main Arena, Bellco Theater, Meeting Room Level
About the Tempo Temporary Pacing Lead
BioTrace Medical’s Tempo Temporary Pacing Lead is designed for secure and stable cardiac pacing with the goal of reducing complications and allowing patients to ambulate sooner after procedures such as TAVR. Cleared by the Food and Drug Administration (FDA) in October 2016, it is the only active fixation temporary pacing lead available in the U.S. The Tempo Lead features a novel active fixation mechanism, bipolar electrodes and a soft tip. This unique design mitigates the risks of dislodgement and perforation. The Tempo Lead ensures stability during rapid pacing and facilitates patient ambulation post-procedure, which can lead to a reduced length of hospital stay.
About BioTrace Medical
BioTrace Medical, Inc., a private venture backed company based in San Carlos, Calif., is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs. For more information, visit www.biotracemedical.com.
